Gaithersburg's National Institute of Standards and Technology (NIST) has awarded a potential $1.5 million to two organizations, with the goal of developing regenerative medicine standards curricula. Brammer Bio, LLC, and Gaithersburg's own Standards Coordinating Body (SCB) for Gene, Cell and Regenerative Medicines and Cell-Based Drug Discovery, will each receive $250,000 per year, with the option to renew for up to three addition years of funding.
Regenerative medicine includes cell therapy, gene therapy, and therapeutic tissue engineering. It relies on the human body's own healing abilities to regenerate or replace damaged organs, cells, and tissue. As a rapidly-growing field in medicine and research, regenerative medicine is a promising new avenue in preventing, treating, and curing cancer and genetic disorders.
NIST was charged by the U.S. Congress last year to help develop the regenerative medicine workforce of the future. It oversaw a competitive process earlier this year, through which the two winning organizations were identified. Now these organizations will endeavor to create training programs on the standards, protocols, and measurements that will provide a foundation for the field going forward.
“We are thrilled to announce our new partnerships to develop an innovative standards education program, paving the way for flexible and immersive learning experiences that support advanced biomanufacturing,” Sheng Lin-Gibson, chief of NIST’s Biosystems and Biomaterials Division, said in a statement this morning. “These educational programs will facilitate the adoption of standards and best practices to increase quality and consistency of advanced therapies and ultimately bring down costs.”
Photo courtesy Robert Rathe/NIST
No comments:
Post a Comment